BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10190716)

  • 1. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment.
    Dalekos GN; Wedemeyer H; Obermayer-Straub P; Kayser A; Barut A; Frank H; Manns MP
    J Hepatol; 1999 Mar; 30(3):366-75. PubMed ID: 10190716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection.
    Duclos-Vallée JC; Nishioka M; Hosomi N; Arima K; Leclercq A; Bach JF; Yamamoto AM
    J Hepatol; 1998 Jun; 28(6):965-70. PubMed ID: 9672171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A major CYP2D6 autoepitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens.
    Sugimura T; Obermayer-Straub P; Kayser A; Braun S; Loges S; Alex B; Lüttig B; Johnson EF; Manns MP; Strassburg CP
    Autoimmunity; 2002 Dec; 35(8):501-13. PubMed ID: 12765476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.
    Klein R; Zanger UM; Berg T; Hopf U; Berg PA
    Clin Exp Immunol; 1999 Nov; 118(2):290-7. PubMed ID: 10540193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease.
    Manns MP; Obermayer-Straub P
    Hepatology; 1997 Oct; 26(4):1054-66. PubMed ID: 9328334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and -positive patients.
    Kitazawa E; Igarashi T; Kawaguchi N; Matsushima H; Kawashima Y; Hankins RW; Miyakawa H
    J Autoimmun; 2001 Nov; 17(3):243-9. PubMed ID: 11712862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of anti-LKM-1(anti-CYP2D6) by an enzyme-linked immunosorbent assay in adult patients with chronic liver diseases.
    Miyakawa H; Kikazawa E; Abe K; Kikuchi K; Fujikawa H; Matsushita M; Kawaguchi N; Morizane T; Ohya K; Kako M
    Autoimmunity; 1999; 30(2):107-14. PubMed ID: 10435724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection.
    Ma Y; Peakman M; Lobo-Yeo A; Wen L; Lenzi M; Gäken J; Farzaneh F; Mieli-Vergani G; Bianchi FB; Vergani D
    Clin Exp Immunol; 1994 Jul; 97(1):94-9. PubMed ID: 8033426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C.
    Miyakawa H; Kitazawa E; Kikuchi K; Fujikawa H; Kawaguchi N; Abe K; Matsushita M; Matsushima H; Igarashi T; Hankins RW; Kako M
    Autoimmunity; 2000; 33(1):23-32. PubMed ID: 11204250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease.
    Kerkar N; Choudhuri K; Ma Y; Mahmoud A; Bogdanos DP; Muratori L; Bianchi F; Williams R; Mieli-Vergani G; Vergani D
    J Immunol; 2003 Feb; 170(3):1481-9. PubMed ID: 12538711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in antigenic sites, recognized by anti-liver-kidney microsome-1 (LKM-1) autoantibody, between HCV-positive and HCV-negative sera in Japanese patients.
    Miyakawa H; Matsushima H; Narita Y; Hankins RW; Kitazawa E; Fujikawa H; Kikuchi K; Matsushita M; Abe K; Kawaguchi N; Morizane T; Kako M
    J Gastroenterol; 1998 Aug; 33(4):529-35. PubMed ID: 9719237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sera of children with hepatitis C infection and anti-liver-kidney microsome-1 antibodies recognize different CYP2D6 epitopes than adults with LKM+/HCV+ sera.
    Herzog D; Yamamoto AM; Jara P; Maggiore G; Sarles J; Alvarez F
    J Pediatr Gastroenterol Nutr; 1999 Nov; 29(5):551-5. PubMed ID: 10554122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece.
    Dalekos GN; Makri E; Loges S; Obermayer-Straub P; Zachou K; Tsikrikas T; Schmidt E; Papadamou G; Manns MP
    Eur J Gastroenterol Hepatol; 2002 Jan; 14(1):35-42. PubMed ID: 11782573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a novel radioligand assay using eukaryotically expressed cytochrome P4502D6 for the measurement of liver kidney microsomal type 1 antibody in patients with autoimmune hepatitis and hepatitis C virus infection.
    Ma Y; Gregorio G; Gäken J; Muratori L; Bianchi FB; Mieli-Vergani G; Vergani D
    J Hepatol; 1997 Jun; 26(6):1396-402. PubMed ID: 9210629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model.
    Hintermann E; Holdener M; Bayer M; Loges S; Pfeilschifter JM; Granier C; Manns MP; Christen U
    J Autoimmun; 2011 Nov; 37(3):242-53. PubMed ID: 21795021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new approach to cytochrome CYP2D6 antibody detection in autoimmune hepatitis type-2 (AIH-2) and chronic hepatitis C virus (HCV) infection: a sensitive and quantitative radioligand assay.
    Yamamoto AM; Johanet C; Duclos-Vallee JC; Bustarret FA; Alvarez F; Homberg JC; Bach JF
    Clin Exp Immunol; 1997 Jun; 108(3):396-400. PubMed ID: 9182882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new epitope of CYP2D6 recognized by liver kidney microsomal autoantibody from japanese patients with autoimmune hepatitis.
    Imaoka S; Obata N; Hiroi T; Osada-Oka M; Hara R; Nishiguchi S; Funae Y
    Biol Pharm Bull; 2005 Dec; 28(12):2240-3. PubMed ID: 16327157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of interferon therapy on Japanese chronic hepatitis C virus patients with anti-liver/kidney microsome autoantibody type 1.
    Iijima Y; Kato T; Miyakawa H; Ogino M; Mizuno M; Sugihara K; Ando T; Fujiwara K; Orito E; Ueda R; Mizokami M
    J Gastroenterol Hepatol; 2001 Jul; 16(7):782-8. PubMed ID: 11446887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection.
    Betterle C; Fabris P; Zanchetta R; Pedini B; Tositti G; Bosi E; de Lalla F
    Diabetes Care; 2000 Aug; 23(8):1177-81. PubMed ID: 10937518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview.
    Dalekos GN; Zachou K; Liaskos C; Gatselis N
    Eur J Intern Med; 2002 Aug; 13(5):293-303. PubMed ID: 12144908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.